

Frequency of Extend Spectrum β -Lactamases Genes among *Klebsiella Pneumoniae* Strains Isolated from Patients Admitted to Shahid Beheshti Hospital, Babol City, Iran

Omid Mohamadi^{1,3}, Ramazan Rajabnia², Abolfazl Davoodabadi³, Soraya Khafri⁴, Amirmorteza Ebrahimzadeh Namvar^{3*}

¹ Student Research Committee, Babol University of Medical Sciences, Babol, Iran. ORCID: 0000-0003-0861-2952

² Infectious Diseases and Tropical Medicine Research Center, Babol University of Medical Sciences, Babol, Iran.

³ Department of Microbiology, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran.

⁴ Department of Biostatistics and Epidemiology, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran.

Received: 2019/01/15 Accepted: 2019/03/9 Published: 2019/06/15

Abstract

Background: Regarding the emergence and increasing of multidrug-resistant strains among *Klebsiella pneumoniae* nosocomial isolates the therapeutic options for the treatment has been limited. The β -lactamases enzymes are the major defense of gram-negative bacteria against antibiotics. The aim of this study was to the detection of *bla*_{CTX-M}, *bla*_{SHV}, and *bla*_{TEM} genes among *K. pneumoniae* strains isolated from patients who admitted to Shahid Beheshti hospital of Babol city, Iran, in 2016. **Materials and Methods:** This study was conducted on 50 samples of *K. pneumoniae* strains isolated from hospitalized patients. Antibiotic susceptibility testing was performed by Kirby-Bauer disc diffusion method according to CLSI guidelines. The *bla*_{CTX-M}, *bla*_{SHV}, and *bla*_{TEM} genes were detected by polymerase chain reaction method. **Result:** Among studied strains, the prevalence of *bla*_{CTX-M}, *bla*_{SHV}, and *bla*_{TEM} genes were 24 (49%), 44 (88%), and 36 (72%), respectively. In this study, imipenem and nitrofurantoin were more effective than other antibiotics. Also, 100% of strains were susceptible to imipenem. **Conclusions:** The prevalence of antibiotic resistance genes detected in this study implies a great concern for the treatment of multidrug-resistant *K. pneumoniae*. Hence, infection control measures, including antibacterial management and identification of resistant isolates for preventing of nosocomial outbreaks have become highlighted.

Keywords: *Klebsiella pneumoniae*, β -Lactamases, Multidrug Resistant, PCR

Introduction

Klebsiella pneumoniae is regarded as an opportunistic pathogen that is effectively adapted to the environmental health care units and can lead to a wide range of community and nosocomial acquired infections, such as urinary tract infections, pneumonia, bloodstream infection, pyogenic liver abscess, etc. After *Escherichia coli*, *K. pneumoniae* is considered as the main cause of nosocomial infections among gram-negative bacteria (1). The high prevalence of multidrug-resistant (MDR) strains among nosocomial infections has made it difficult to select the appropriate drug for the treatment of *K. pneumoniae* (2). Several virulence factors have been identified in *K. pneumoniae*, the most important of which are capsule and bacterial adhesions including type 1 and 3 fimbriae for binding to host cells (3).

TEM, SHV, and CTX-M, OXA are the most important β -lactamases of *K. pneumoniae*. *K. pneumoniae* is one of the most prevalent extend spectrum β -lactamases (ESBL)-producing bacteria belonging to family Enterobacteriaceae (4). The ESBL-producing *K. pneumoniae* strains are increasing, while in the 1980s the first strain was described. Currently, ESBL-producing strains have reported from various microorganisms such as *E. coli*, *Pseudomonas aeruginosa*, *Serratia marcescens*, etc. (5). Because of the potential transmission of this bacteria at the hospital and the acquisition of antibiotic resistance genes, the level of infections caused by this microorganism has increased and has led to a health problem. Therefore, knowing the pattern of antibiotic resistance and pathogenic factors can help treat (6). This study aimed to evaluate antibiotic susceptibility and detecting the *bla*_{CTX-M}, *bla*_{SHV}, and *bla*_{TEM} genes.

*Corresponding Author:

Amirmorteza Ebrahimzadeh Namvar, Department of Microbiology, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran.

Telephone Number: +989124140542

Email Address: Amirmorteza.namvar@gmail.com

ORCID: 0000-0003-2654-9643



Materials and Methods

Collecting and identifying isolates

This study was conducted on *K. pneumoniae* strain isolates from 50 patients who admitted at Shahid Beheshti hospital among clinical samples including urine (n=37), blood (n=10) and sputum (n=3) over six months in 2016. The *K. pneumoniae* strains were identified and confirmed by standard biochemical and microbiological tests.

Antibiotic susceptibility testing

The antibiotic susceptibility test was performed by the disc diffusion method using Mueller Hinton agar plates according to the CLSI guidelines as follows: imipenem (10µg), aztreonam (30µg), nitrofurantoin (300µg), ceftazidime (30µg), amikacin (30µg), cefepime (30µg), piperacillin (100µg), ciprofloxacin (5µg), cefotaxime (30 µg), co-trimoxazole (25µg), cefixime (5µg), and ceftriaxone (µg) that obtained from Rosco (Denmark) (7).

DNA extraction and polymerase chain reaction (PCR) identification

The DNA was extracted by commercial Roche kit (Germany) as recommended by the manufacturer. After that, *bla_{TEM}*, *bla_{CTX-M}* and *bla_{SHV}* genes were detected by specific universal primers (Gene Fanavaran Co, Tehran, Iran). Primers details are listed in Table-1. The PCR steps for each gene amplification were as follow: Initial denaturation step at 95°C for 5 min, denaturation at 94°C for 45 s, annealing at 60°C for 30 s for *bla_{SHV}*, *bla_{TEM}* and 59°C for *bla_{CTX-M}* extension at 72°C for 1 min followed by 30 cycles, then a final extension step at 72°C for 5 min. Finally, the PCR products were electrophoresed on 1% agarose gel.

Result

Among a total of 50 *K. pneumoniae* strains, the prevalence of *bla_{CTX-M}*, *bla_{SHV}* and *bla_{TEM}* genes were 24 (49%), 44 (88%), and 36 (72%), respectively (Figure-1

and 3). In antimicrobial susceptibility assay, imipenem and nitrofurantoin were more effective than other antibiotics, in which 100% of strains were susceptible to imipenem, 60% of strains were resistant to ceftazidime, and 38% of strains were sensitive to cefotaxime (Table-2). On the other hand, 68% and 32% of strains were distinguished as MDR and non-MDR (Table-3).

Discussion

K. pneumoniae is a gram-negative bacteria that play an important clinical role in the hospital developed infections and also a urinary tract infection. The excessive use of antibiotics in recent decades has been led to an increase in the emergence of resistant strains with MDR in gram-negative bacteria such as *K. pneumoniae* with the ability to produce different enzymes (8). The ESBL are resistant to several antibiotics such as cephalosporins, penicillins, ciprofloxacin, cefotaxime, etc. The presence and transmission of genes that encoding the beta-lactamase enzymes among gram-negative bacteria have become a major global concern because the ESBL-producing strains are also resistant to other types of antibiotics (9, 10). The results of this study indicate that the imipenem with 100% susceptibility was the most effective antibiotic against *K. pneumoniae* strains isolated from clinical specimens that this issue has been proven in similar studies (11, 12). However, in a similar study, the susceptibility of imipenem in *K. pneumoniae* was described 94.9% (13). *K. pneumoniae* imipenem-resistant strains are reported at a low level in most studies, though the discriminative usage may lead to the emergence of resistant strains to both imipenem and meropenem antibiotics. In the present study, the resistance to cefotaxime, ceftriaxone, and cefixime were reported 58%, 32%, and 30%, respectively. However, the antimicrobial susceptibility pattern was achieved 41% and 37.2% by Eftekhar *et al.* for ceftazidime and ceftriaxone, respectively (14). While in a study conducted in Saudi Arabia in 2009, resistance to ceftazidime was reported 97% (15). Saeidi *et al.* study in Zabol city indicated that the resistance rate for third-generation cephalosporins such as ceftriaxone

Table 1. Specific PCR primers for detection of *SHV*, *TEM* and *CTX-M* genes

Gene name	Primer name	Nucleotide sequence (5'-3')	Amplicon size (bp)
<i>bla_{CTXM}</i>	CTX-M-F	ATGTGCAGYACCAGTAARGTKATGGC	593 bp
	CTX-M-R	TGGGTRAARTARGTSACCAGAAAYCAGCGG	
<i>bla_{SHV}</i>	SHV-F	CGCCTGTGTATTATCTCCCT	293 bp
	SHV-R	CGAGTAGTCCACCAGATCCT	
<i>bla_{TEM}</i>	TEM-F	TTTCGTGTCGCCCTTATTC	403 bp
	TEM-R	ATCGTTGTCAGAAGTAAGTTGG	




Figure 1. The result of PCR for *bla_{TEM}* gene. C-pos: Positive control, C-neg: Negative control, Left line: 100bp DNA ladder, Line 1: negative isolate, Line 2 and 3: Positive isolates (403bp).

and ceftazidime was 100% (16). These various results may be due to uncontrolled consumption of antibiotics, the emergence of resistant strains, and therapeutic regimen management by PCR, 44 (88%) and 36 (72%) of all strains harbored *bla_{SHV}* and *bla_{TEM}* genes, respectively. Similar results in Turkey showed that 74.3% of *E. coli* and *K. pneumoniae* strains had *bla_{SHV-I}* and also 52.7% of them have *bla_{TEM-I}* (17). Due to recent studies that have been conducted all around the world, the *bla_{TEM}* mutation in *K. pneumoniae* is related to each statistical study population, for example in the study of Akpaka *et al.* in 2010, 84.3% of isolates had the *bla_{TEM}* gene (13). In Bali *et al.* study in Turkey (2010), the prevalence of *bla_{TEM}* gene was reported 74.4% similar to Pornour *et al.* in 2010 (18, 19). Whereas, the conducted researches

in 2007 and 2009 on *K. pneumoniae* strains showed the prevalence of *bla_{TEM}* gene was 80% and 25%, respectively (20, 21). Another similar study in Shiraz during 2009-2010 indicated that 60% of isolates were ESBL-producers. The *bla_{TEM}* was reported in 38.3%, both *bla_{CTX-M}* and *bla_{TEM}* in 39%, and 13% harbored *bla_{TEM}*, *bla_{SHV}* and *bla_{CTX-M}* (5). Ghafourian *et al.* reported that among 67 isolated samples of *K. pneumoniae* producing ESBLs, 94% were positive for *bla_{SHV}*, 16.4% contained *bla_{TEM}* and 23.9% harbored *bla_{CTX-M}*. On the other hand, 20.9% of isolates had both *bla_{CTX-M}* and *bla_{SHV}* genes, 13.4% carried both *bla_{SHV}* and *bla_{TEM}* and 6% were positive for *bla_{TEM}* and *bla_{CTX-M}* (22). The results of this study indicated an increase in the resistance of *K. pneumoniae* strains to the trimethoprim/sulfamethoxazole and cef-




Figure 2. The result of PCR for *bla_{SHV}* C-pos: Positive control, C-neg: Negative control, Left line: 100bp DNA ladder, Line 1, 2 and 3: Positive isolates (293bp).




Figure 3. The result of PCR for *bla_{CTX-M}* C-pos: Positive control, Left line: 100bp DNA ladder, Line 1, 2 and 3: Positive isolates (593bp).

Table 2. The frequency of susceptibility and resistant antibiotics among isolated *K. pneumoniae* strains

Antibiotics	Resistant N (%)	Sensitive N (%)	Intermediate N (%)
Ceftazidime	30 (60%)	20 (40%)	-
Cefotaxime	29 (58%)	19 (38%)	2 (4%)
Ciprofloxacin	20 (40%)	29 (58%)	1 (2%)
Ceftriaxone	16 (32%)	32 (64%)	2 (4%)
Co-trimoxazole	19 (38%)	30 (60%)	1 (2%)
Imipenem	-	50 (100%)	-
Aztreonam	22 (44%)	26 (52%)	2 (4%)
Amikacin	18 (36%)	31 (62%)	1 (2%)
Nitrofurantoin	12 (24%)	36 (72%)	2 (4%)
Cefepime	13 (26%)	35 (70%)	2 (4%)
Cefixime	15 (30%)	34 (68%)	1 (2%)
Piperacillin	26 (52%)	22 (44%)	2 (4%)

Table 3. The distribution of MDR among isolated *K. pneumoniae* strains

Antibiotic Name	N (%)
CAZ-CTX-CIPR-CRO-AMI-AZT-CO-FEP-CFM-PIPRA	3 (6%)
CAZ-CTX-CIPR-CO-AZT-AMI-FM-FEP-PIPRA	4 (8%)
CTX-CIPR-CRO-CO-AZT-AMI-CFM-FEP-CAZ	2 (4%)
CAZ-FM-CTX-CIPR-CFM-CO-AMI-PIPRA	4 (8%)
CAZ-CTX-CIPR-FM-AZT-CFM-PIPRA-CRO	2 (4%)
CAZ-CTX-CIPR-FM-AZT-CFM-AMI	1 (2%)
CTX-CFM-CO-CAZ-CRO-PIPRA	2 (4%)
CTX-CIPR-AZT-AMI-FEP-CAZ	1 (2%)
CTX-CIPR-CO-AZT-FEP-AMI	3 (6%)
CAZ-CTX-CRO-AZT-PIPRA	4 (8%)
CRO-AZT-FM-PIPRA-CIPR	1 (2%)
CAZ-CTX-PIPRA-CRO	4 (8%)
CAZ-CTX-PIPRA-CFM	2 (4%)
CAZ-CTX-AZT-CO	1 (2%)

Ceftazidime-Cefotaxime (CTX) -Ciprofloxacin (CP) -Ceftriaxone (CRO) -Aztreonam (AZT) -Amikacin (AN)
Nitrofurantoin-Cefepime (FEP)-Cefaxime (CFM)-Piperacillin (PIPRA) - Co-trimoxazole (CO)

triaxone antibiotics. In conclusion, preventing and also controlling MDR strains is considered as an important issue in the treatment of infections. On the other hand, the insufficient information about the frequency of these genes and genetic patterns can be led to the increase of antibiotic resistance prototype in Iran. Therefore, the detection of *K. pneumoniae* strains containing beta-lactamase resistance enzymes is important for better treatment and preventing the outbreak of these genes.

Acknowledgment

This study was supported by the Babol University of Medical Science. (Ethics code: MUBABOL.REC.1395.75)

Conflict of interest

The authors declare that there is no conflict of interest.

References

- Zamani A, Yousefi Mashouf R, Ebrahimzadeh Namvar A, Alikhani MY. Detection of magA Gene in *Klebsiella* spp. Isolated from clinical samples detection of magA. Iran J Basic Med Sci. 2013; 16(2): 173.
- Heydarpour M, Amini A, Ebrahimzadeh Namvar A. Evaluation of *Kpn* and *mrkD* genes among *klebsiella pneumoniae* strains isolated from patients admitted to different wards of Rouhani and Shahid Beheshti Hospitals of Babol, Iran. Avicenna J Clin Med. 2018; 24(4):330-5. Doi: 10.21859/ajcm.24.4.330.
- Stahlhut SG, Chattopadhyay S, Struve C, Weissman SJ, Aprikian P, Libby SJ, et al. Population variability of the *FimH* type 1 fimbrial adhesin in *Klebsiella pneumoniae*. J Bacteriol. 2009; 191(6):1941-50. Doi: 10.1128/JB.00601-08.
- Cornista JC, Cuña AMD, Sanchez HJA, Balolong MP. Detection of extended-spectrum β -lactamase-producing *klebsiella pneumoniae* isolated from four provincial Hospitals in Luzon and Genotyping of β -lactamase (*bla*_{CTX-M}, *bla*_{TEM}, *bla*_{SHV} and *bla*_{OXA}) genes. Philipp J Sci. 2019; 148(2):277-87.
- Kollmann TR, Crabtree J, Rein-Weston A, Blimkie D, Thommai F, Wang XY, et al. Neonatal innate TLR-mediated responses are distinct from those of adults. J Immunol. 2009; 183(11):7150-60. Doi: 10.4049/jimmunol.0901481.
- Hossieni SE, Amini A, Soltanmoradi H, Ebrahimzadeh Namvar A. Frequency of *fimH*, *magA* and *rmpA* genes among *klebsiella pneumoniae* isolates in hospitalized patients in Babol, Iran. Avicenna J Clin Med. 2018; 25(2):121-6. Doi: 10.21859/ajcm.25.2.121.
- Clinical and Laboratory Standards Institute. M100S: Performance Standards for Antimicrobial Susceptibility Testing. 26th ed. Wayne: Clinical and Laboratory Standards Institute; 2016.

- Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med. 2010; 362(19):1804-13. Doi: 10.1056/NEJMra0904124.
- Paterson DL, Ko W-C, Gottberg AV, Mohapatra S, Casellas JM, Goossens H, et al. International prospective study of *klebsiella pneumoniae* bacteremia: implications of extended-spectrum β -lactamase production in nosocomial infections. Ann Intern Med. 2004; 140:26-32. Doi: 10.7326/0003-4819-140-1-200401060-00008.
- Yusuf I, Haruna M, Yahaya H. Prevalence and antibiotic susceptibility of ampc and ESBL producing clinical isolates at a tertiary health care center in Kano, northwest Nigeria. AJCEM. 2013; 14(2):109-19.
- Abbasian A, Pir Bux G, Shagufta H, Alya Javed H, et al. Prevalence of antibiotic resistance among clinical isolates of *klebsiella pneumoniae* isolated from a tertiary care hospital in Pakistan. Malays J Microbiol. 2009; 5(2):81-6. Doi: 10.21161/mjm.13409.
- Soltan Dalal MM, Miremadi SA, Sharify Yazdi MK, Rastegar Lari A, Rajabi Z, Avadis Yans S. Antimicrobial resistance trends of *klebsiella* spp. isolated from patients in Imam Khomeini Hospital. Payavard. 2012; 6(4):275-81. [Persian]
- Akpaka PE, Legall B, Padman J. Molecular detection and epidemiology of extended-spectrum beta-lactamase genes prevalent in clinical isolates of *klebsiella pneumoniae* and *E.coli* from trinidad and tobago. West Indian Med J. 2010; 59(6):591-6.
- Eftekhari F, Rastegar M, Golalipoor M, Mansoursamaei N. Detection of extended spectrum B-lactamases in urinary isolates of *klebsiella pneumoniae* in relation to *blaSHV*, *blaTEM* and *blaCTX-M* gene carriage. Iran J Public Health. 2012; 41(3):127-32. PMID: 23113157.
- Al-Agamy MHM, Shibl AM, Tawfik AF. Prevalence and molecular characterization of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* in Riyadh, Saudi Arabia. Ann Saudi Med. 2009; 29(4):253-7. Doi: 10.4103/0256-4947.55306.
- Saeidi SGM, Taheri R, Shirri Y, Solouki M, Hassanpour K, Farnoosh G. Phenotypic and genotypic detection of extended-spectrum β -lactamase (ESBL) producing *Escherichia coli* isolated from urinary tract infections in Zabol, Iran. J Coast Life Med. 2014; 2(9):732-7. Doi: 10.12980/JCLM.2.2014JCLM-2014-0063.
- Tasli H, Bahar IH. Molecular characterization of *TEM*-and *SHV*-derived extended-spectrum beta-lactamases in hospital-based Enterobacteriaceae in Turkey. Jpn J Infect. 2005; 58(3):162-7.
- Bali EB, Acik L, Sultan N. Phenotypic and molecular characterization of *SHV*, *TEM*, *CTX-M* and extended spectrum-lactamase produced by *Escherichia coli*, *Acinobacterbaumannii* and *Klebsiella* isolates in a Turkish hospital. Afr J Microbiol Res. 2010; 4(8):650-4.
- Pornour M, Nahae MR, Mobayen H, Mobasher AR. Molecular study of TEM type extended-spectrum beta-lactamase genes in *Escherichia coli* and *klebsiella pneumoniae* isolates. MJTUOMS. 2010; 32(2):30-4.

[Persian]

20. Masjedian F, Valehi F, Talebi A, Rastegar Lari A. Evaluation of wide broad spectrum antibiotic resistance of *E. coli* and *Klebsiella pneumonia*. Iran J Med Microbiol. 2007; 1(2):27-34. [Persian]

21. Mobasher Kare Jeddi A, Nahaei M, Mobayyen H, Pornour M, Sadeghi J. Molecularstudy of extended spectrum beta-lactamase (SHV type) in *Esherichia coli* and *Klebsiella pneumoniae* isolated from Medical Centers of Tabriz. Iran J Med Microbiol. 2009; 2(3 and 4):9-17. [Persian]

22. Ghafourian S, Sekawi ZB, Sadeghifard N, Mohebi R, KumariNeela V, Maleki A, et al. The Prevalence of ESBLs producing isolates *Klebsiella pneumoniae* in some major hospitals, Iran. Open Microbiol J. 2011; 5:91-5. Doi: 10.2174/1874285801105010091.